Oral Tebipenem Pivoxil Hydrobromide versus Intravenous Imipenem-Cilastatin in Patients with Complicated Urinary Tract Infections or Acute Pyelonephritis: efficacy and Safety Results from the Phase 3 PIVOT-PO study

Authors
Category Primary study
ConferenceOpen forum infectious diseases
Year 2026
This article has no abstract
Epistemonikos ID: e1c739b316be1cd6de6d853736e10f39f5856ae9
First added on: Mar 21, 2026